Admilparant is an investigational lysophosphatidic acid receptor 1 (LPA1) antagonist currently in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary… Read more
Admilparant is an investigational lysophosphatidic acid receptor 1 (LPA1) antagonist currently in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). As this first-in-class agent progresses through clinical trials, comprehensive analytical oversight is essential for characterization and regulatory compliance. This category provides access to high-quality reference standards of the Admilparant active pharmaceutical ingredient, alongside its related pharmacopeial and non-pharmacopeial impurities. These compounds are critical for rigorous impurity profiling, method validation, and stability testing within pharmaceutical quality control workflows. Additionally, researchers rely on stable isotope-labelled compounds in this collection as internal standards for sensitive mass spectrometry-based bioanalytical assays, ensuring accuracy when quantifying drug levels in complex biological matrices during pharmacokinetic studies and ongoing clinical evaluations.